Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Catalyst Pharmaceuticals Q3 2025 Earnings Call - Robust Rare Disease Portfolio Fuels Record Revenue and Raised Guidance
Catalyst Pharmaceuticals reported a strong third quarter in 2025, driven by record revenues of $148.4 million, a 15.3% year-over-year increase led by its rare disease therapies Firdapse, AGAMREE, and ...
- Catalyst achieved record Q3 2025 revenue of $148.4 million, up 15.3% year-over-year driven by rare disease therapies.
- Firdapse revenue rose 16.2% year-over-year to $92.2 million, maintaining leadership in treating Lambert-Eaton Myasthenic Syndrome (LEMS).
- About 90% of cancer-associated LEMS patients remain undiagnosed, signaling significant growth potential for Firdapse with ongoing efforts to increase VGCC antibody testing and oncology guideline adoption.
- +7 more takeaways
Himalaya Shipping Q3 2025 Earnings Call - Navigating Market Upside with Strategic Fixed Charters and Fleet Premium
Himalaya Shipping reported a net profit of $9.5 million in Q3 2025, alongside an EBITDA of $29.3 million, reflecting slight softness compared to the previous year as time charter equivalent earnings d...
- Himalaya Shipping posted a Q3 2025 net profit of $9.5 million and EBITDA of $29.3 million, slightly down from Q3 2024.
- Gross time charter equivalent earnings averaged $35,600 per day, down from $36,800 the prior year.
- The company converted eight vessels from index-linked to fixed-rate charters with rates around $35,300 to $38,500 per day, mitigating earnings volatility.
- +12 more takeaways
Dentsply Sirona Q3 2025 Earnings Call - CEO Outlines Bold Return-to-Growth Plan Amid US Sales Struggles
In his first 90 days, CEO Dan Scavilla painted a candid picture of Dentsply Sirona's Q3 2025 performance, marked by a 5% sales decline and a heavy $263 million goodwill impairment linked to tariffs an...
- Q3 2025 global sales declined 5% as reported, 8% on a constant currency basis, with U.S. sales down 22.2%.
- Excluding a prior-year $24 million dealer pre-buy impact, sales decline narrows to 2.5% on constant currency.
- Adjusted EBITDA rose 50 basis points to 18.4%, helped by favorable product/geography mix and tariff impacts offset by lower OPEX.
- +17 more takeaways
Teads Q3 2025 Earnings Call - Navigating Integration Challenges While Betting on CTV and AI for Growth
Teads reported a challenging third quarter 2025 marked by integration complexities post-merger and a softer-than-expected revenue environment in key markets including the U.S., U.K., and France. Despi...
- Teads’ Q3 2025 revenue grew 42% year-over-year on an as-reported basis but declined 15% pro forma, reflecting merger integration headwinds and softness in core markets.
- Integration complexity between legacy businesses slowed performance and led to a revenue shortfall versus guidance for ex-tech gross profit and adjusted EBITDA.
- Connected TV (CTV) is Teads’ fastest-growing segment, up roughly 40% year-over-year and expected to reach $100 million revenue by year-end.
- +12 more takeaways
Prestige Consumer Healthcare Q2 2026 Earnings Call - Clear Eyes Supply Chain Recovery and Strategic Growth Amid Supply Constraints
Prestige Consumer Healthcare reported Q2 2026 results with revenues slightly down due to Clear Eyes supply constraints but ahead of expectations thanks to timing and accelerated e-commerce shipments. ...
- Q2 2026 revenue of $274 million declined 3.4% year-over-year, mainly due to Clear Eyes supply constraints and expected cough & cold category weakness.
- Adjusted EPS of $1.07 matched prior year but beat Street expectations due to timing and accelerated e-commerce shipments.
- Clear Eyes supply chain disruptions are easing with two new suppliers operational and Pillar Five's high-speed production line ramping, supporting sequential improvement through Q3 and Q4.
- +13 more takeaways
BlackSky Technology 3Q 2025 Earnings Call - Strong International Demand and Gen-3 Momentum Drive Growth Outlook
BlackSky Technology’s third quarter 2025 results reveal a clear pivot toward international markets and the accelerating deployment of its Gen-3 satellite constellation. Despite near-term U.S. governme...
- BlackSky awarded over $60 million in new contracts primarily with international customers, showing diversification and strong demand for Gen-3 services.
- More than 90% of BlackSky's backlog is attributed to international contracts for Gen-3 capabilities, shifting revenue composition seasonally from U.S. government dominance.
- Gen-3 constellation deployment is progressing, with the next satellite at launch site despite a minor production delay; target of 12 operational Gen-3 satellites by end of 2026 remains intact.
- +13 more takeaways
Lexicon Pharmaceuticals Q3 2025 Earnings Call - Advancing Pipeline with Pilobafidin Phase 3 Readiness and Accelerated HCM Trial Enrollment
Lexicon Pharmaceuticals reported solid progress in Q3 2025, reinforcing its strategic pivot to R&D focused on cardiometabolic diseases. Pilobafidin showed promising phase 2 results supporting phase 3 ...
- Pilobafidin’s phase 2 program demonstrated consistent, clinically meaningful pain reduction in diabetic peripheral neuropathic pain (DPNP), validating 10mg dose for phase 3 development.
- FDA granted Lexicon an end-of-phase 2 meeting for pilobafidin; written feedback expected early 2026, critical for phase 3 trial design confirmation.
- IND enabling studies for LX9851, a novel obesity candidate, are complete; partnered with Novo Nordisk under an exclusive license with potential $30 million near-term milestones.
- +13 more takeaways
NCR Atleos Q3 2025 Earnings Call - Robust Hardware and ATM as a Service Drive Steady Growth Amid Tariff Uncertainty
NCR Atleos delivered a steady third-quarter performance, extending its consistent track record since separating from legacy NCR over two years ago. The company showcased 6% core top-line growth and 7%...
- NCR Atleos marked its seventh quarter as an independent publicly traded company with consistent, predictable financial performance.
- Core top-line revenue grew 6% year-over-year in Q3, led by a 24% surge in hardware sales and 37% growth in ATM as a Service revenue.
- Hardware strength was driven by increased demand for next-generation recycler ATMs and record production from the Chennai manufacturing facility.
- +9 more takeaways
Chimera Investment Corporation Q3 2025 Earnings Call - Home Express Acquisition Accelerates Growth and Diversification
Chimera Investment Corporation’s third quarter 2025 earnings call was dominated by the strategic acquisition of Home Express Mortgage, closed on October 1 for approximately $267 million. The deal adds...
- Chimera closed the Home Express Mortgage acquisition on October 1, 2025, for $267 million including cash and stock components, marking a major strategic expansion.
- Home Express operates in the non-QM mortgage market, a sector that has surged from 1.1% to over 5% of total residential originations since 2021, with projected growth to $110-$150 billion in 2026.
- The acquisition met Chimera’s criteria of aligned management, profitability, and synergy potential, especially given Home Express’s disciplined growth and quality of production.
- +7 more takeaways
Centrus Energy Q3 2025 Earnings Call - Preparing for Scaling Up Enrichment Amid Rising Nuclear Demand and Market Tightness
Centrus Energy's Q3 2025 results reveal a company positioning aggressively for a surge in nuclear fuel enrichment demand. Despite a third-quarter gross loss, net income surged year-to-date to $60 mill...
- Centrus reported Q3 revenue of $74.9 million, net income of $3.9 million, and year-to-date net income of $60 million compared to $19.5 million in 2024.
- The firm's LEU segment revenue grew 29% YoY driven by increased uranium sales volumes despite lower SWU pricing; technical solutions revenue increased 31%.
- Gross loss of $4.3 million in Q3 due to rising costs linked to higher volumes and HALO contract cost increases.
- +12 more takeaways